NCT06956300Recruiting
TMS for Cognitive Decline in Aging and Preclinical AD
Grit Against Cognitive Decline in Aging and Preclinical Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease. This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 14 Apr 2025
- Start date
- 7 Apr 2025
- Primary completion date
- 31 Aug 2029
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06956300
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 7 Apr 2025 to the primary completion date, 31 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.
Other illness
- History of head trauma involving loss of consciousness or alteration in consciousness
- Another major neurologic or psychiatric condition
- Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
- Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
- History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).
- Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.
Other
- Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
- Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
- Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging
Who the study is looking for
- Between the ages of 40-99
- Native English speakers
- Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
- Cognitively normal older adults and individuals with preclinical Alzheimer's disease will be included.
Age in the registry: 40 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.